VIRIDIAN THERAPEUTICS INC (VRDN) Stock Price, Quote, News and Overview
NASDAQ:VRDN - Nasdaq - US92790C1045 - Common Stock - Currency: USD
VRDN Quote, Performance and Key Statistics
16.27
-0.35 (-2.11%)
The current stock price of VRDN is 16.27 USD. In the past month the price decreased by -13.27%. In the past year, price decreased by -13.32%.
VRDN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About VRDN
Company Profile
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. The company is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Company Info
VIRIDIAN THERAPEUTICS INC
221 Crescent Street, Suite 103A
Waltham MASSACHUSETTS 80301 US
CEO: Jonathan Violin
Employees: 94
Company Website: https://www.viridiantherapeutics.com/
Investor Relations: https://investors.viridiantherapeutics.com/
Phone: 16172724600
VIRIDIAN THERAPEUTICS INC / VRDN FAQ
What is the stock price of VIRIDIAN THERAPEUTICS INC today?
The current stock price of VRDN is 16.27 USD. The price decreased by -2.11% in the last trading session.
What is the ticker symbol for VIRIDIAN THERAPEUTICS INC stock?
The exchange symbol of VIRIDIAN THERAPEUTICS INC is VRDN and it is listed on the Nasdaq exchange.
On which exchange is VRDN stock listed?
VRDN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VIRIDIAN THERAPEUTICS INC stock?
23 analysts have analysed VRDN and the average price target is 41.25 USD. This implies a price increase of 153.51% is expected in the next year compared to the current price of 16.27. Check the VIRIDIAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VIRIDIAN THERAPEUTICS INC worth?
VIRIDIAN THERAPEUTICS INC (VRDN) has a market capitalization of 1.29B USD. This makes VRDN a Small Cap stock.
How many employees does VIRIDIAN THERAPEUTICS INC have?
VIRIDIAN THERAPEUTICS INC (VRDN) currently has 94 employees.
What are the support and resistance levels for VIRIDIAN THERAPEUTICS INC (VRDN) stock?
VIRIDIAN THERAPEUTICS INC (VRDN) has a support level at 16.26 and a resistance level at 18.44. Check the full technical report for a detailed analysis of VRDN support and resistance levels.
Is VIRIDIAN THERAPEUTICS INC (VRDN) expected to grow?
The Revenue of VIRIDIAN THERAPEUTICS INC (VRDN) is expected to decline by -15.41% in the next year. Check the estimates tab for more information on the VRDN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VIRIDIAN THERAPEUTICS INC (VRDN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRDN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRDN, evaluating the profitability, health, valuation and growth aspects
- VIRIDIAN THERAPEUTICS INC (VRDN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIRIDIAN THERAPEUTICS INC (VRDN) Sales and EPS estimates to see what analysts future expectations are.
- VIRIDIAN THERAPEUTICS INC (VRDN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIRIDIAN THERAPEUTICS INC (VRDN) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIRIDIAN THERAPEUTICS INC (VRDN) Stock Chart to make your own analysis
- VIRIDIAN THERAPEUTICS INC (VRDN) Latest news and press-releases to stay up to date.
Does VIRIDIAN THERAPEUTICS INC (VRDN) stock pay dividends?
VRDN does not pay a dividend.
When does VIRIDIAN THERAPEUTICS INC (VRDN) report earnings?
VIRIDIAN THERAPEUTICS INC (VRDN) will report earnings on 2025-05-06, after the market close.
What is the Price/Earnings (PE) ratio of VIRIDIAN THERAPEUTICS INC (VRDN)?
VIRIDIAN THERAPEUTICS INC (VRDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.31).
What is the Short Interest ratio of VIRIDIAN THERAPEUTICS INC (VRDN) stock?
The outstanding short interest for VIRIDIAN THERAPEUTICS INC (VRDN) is 14.25% of its float. Check the ownership tab for more information on the VRDN short interest.
VRDN Technical Analysis
VRDN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRDN. VRDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VRDN Financial Highlights
Over the last trailing twelve months VRDN reported a non-GAAP Earnings per Share(EPS) of -4.31. The EPS increased by 15.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.31% | ||
| ROE | -36.34% | ||
| Debt/Equity | 0.03 |
VRDN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to VRDN. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of 23.58% and a revenue growth -15.41% for VRDN